Who Benefits Most from Tirzepatide Among Patients with Type 2 Diabetes?

Scherger, Joseph E. MD, MPH

Core Faculty, Eisenhower Health Family Medicine, Residency Program, Eisenhower Health Center, La Quinta, CA; Clinical Professor, Keck School of Medicine, University of Southern California, Los Angeles

Financial Disclosure: Dr. Stephen Brunton, physician editor, reports he is on the speakers bureau for AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, and Sanofi; is a retained consultant for AstraZeneca, Novo Nordisk, and Sanofi; and is a stockholder with Paracrine. The relevant financial relationships listed have been mitigated. None of the remaining planners or authors for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Internal Medicine Alert 45(24):p 185-186, December 30, 2023.

SYNOPSIS: Females, patients of white or Asian race, younger patients, and those taking metformin benefit the most from treatment with tirzepatide.

SOURCE: Malecki MT, Batterham RL, Sattar N, et al. Predictors of ≥ 15% weight reduction and associated changes in cardiometabolic risk factors with tirzepatide in adults with type 2 diabetes in SURPASS 1-4. Diabetes Care 2023;46:1-8.